title: [Life-threatening ketoacidosis in a 25-year-old woman treated with sodium-glucose cotransporter 2 inhibitor].
abstract: We report a case of atypical ketoacidosis in a patient treated with a sodium-glucose cotransporter- (SGLT) 2 inhibitor. The 25-year-old woman, who one year earlier had been prescribed dapagliflozin for presumed Type 2 diabetes, came to the emergency department in a state of severe ketoacidosis, pH 6.85, and a plasma glucose level of 14.3 mmol/l. She received standard treatment and recovered. We discuss the increasing evidence for atypical ketoacidosis being a serious side effect of the SGLT2 inhibitors.
authors.affiliation: mli@dadlnet.dk.
authors.forename: Mats Jacob Hermansson
authors.initials: MJ
authors.lastname: Lindberg
authors.forename: Frans Brandt
authors.initials: FB
authors.lastname: Kristensen
authors.forename: Alev
authors.initials: A
authors.lastname: Yildiz
mesh_terms: D000328:Adult; D001559:Benzhydryl Compounds / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D016883:Diabetic Ketoacidosis / Q000139:chemically induced* / Q000628:therapy; D005260:Female; D005960:Glucosides / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000077203:Sodium-Glucose Transporter 2 Inhibitors
chemical_list: D001559:Benzhydryl Compounds; D005960:Glucosides; D007004:Hypoglycemic Agents; D000077203:Sodium-Glucose Transporter 2 Inhibitors; C529054:dapagliflozin